CTOs on the Move

Savara Pharmaceuticals

www.savarapharma.com

 
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.savarapharma.com
  • 6836 Bee Cave Road Building 3, Suite 200
    Austin, TX USA 78746
  • Phone: 512.961.1891

Executives

Name Title Contact Details

Funding

Savara Pharmaceuticals raised $18.54M on 12/17/2015
Savara Pharmaceuticals raised $47M on 10/26/2017
Savara Pharmaceuticals raised $26.8M on 01/15/2020
Savara Pharmaceuticals raised $130M on 03/11/2021

Similar Companies

Redox Pharmaceutical

Redox Pharmaceutical Corp. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teva Canada Innovations.

Sudmo North America

Sudmo North America is a Machesney Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease.   Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.

Medizone International

Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices. The company developed the AsepticSure® System to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets, through its expanding distributor network. The AsepticSure® System is EPA-approved, received the CE mark and is currently pursuing FDA 510(k) registration.